ABBV vs QURE

AbbVie Inc. (ABBV) is a well-established mega-cap pharmaceutical company with a robust product portfolio, strong financial health, and a leading position in key therapeutic areas. It excels as a stable dividend payer and a defensive holding. However, its fundamental characteristics, including its immense market capitalization ($397.29B), the mature nature of the pharmaceutical industry, high R&D c...

uniQure's previous 10x potential, primarily tied to AMT-130 for Huntington's disease, has been severely hampered by recent developments. The FDA's criticism of the study design, requiring additional studies and delaying the BLA submission, coupled with multiple securities class-action lawsuits, represents a significant setback. While the long-term market opportunity for gene therapy in rare diseas...